BioNTech Settles Royalty Dispute with University of Pennsylvania

The latest update is out from BioNTech SE ( (BNTX) ).

Don't Miss Our Christmas Offers:

BioNTech SE has reached a settlement agreement with the University of Pennsylvania over a royalty dispute related to its COVID-19 vaccine, developed in collaboration with Pfizer. The agreement involves a payment of up to $467 million to Penn, which includes royalties for past sales and funding for extended research collaboration. Pfizer has also agreed to reimburse BioNTech for part of these royalties.

More about BioNTech SE

BioNTech SE is a biotechnology company primarily focused on developing and manufacturing immunotherapies for the treatment of cancer and infectious diseases. The company is well-known for its role in developing one of the first COVID-19 vaccines in collaboration with Pfizer.

YTD Price Performance: 7.80%

Average Trading Volume: 820,259

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $27.28B

Learn more about BNTX stock on TipRanks’ Stock Analysis page.

Trending Articles

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.